IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announces its revenue for its second quarter and first half to 30 June, 2015.
Ludovic Lastennet, CEO of Implanet, says: “During the 1st half of the year, commercial activity was led by the substantial increase in Spine sales, marking uninterrupted growth over the last 18 months in our priority regions. We estimate the number of surgeries carried out with the JAZZ implant at more than 600 over the first 6 months of the year. This validates our strategy of focusing our JAZZ implant at regions of the world with the greatest potential. In accordance with our roadmap, the extension of the range launched in late May is beginning to bear fruit, accounting for approximately 20% of 1st half revenue. Moreover, the first surgeries in Latin America are an encouraging sign, this region has all the characteristics of the priority markets we are targeting. France is now headed by a dedicated Sales Director, Ludivine Wagner-Pellegrini, and is recording solid JAZZ sales growth.”
Further buoyant growth in JAZZ sales over the half, notably in the United States
In H1 2015, Implanet recorded revenue of €3,306 thousand (+2.2% vs. €3,236 thousand in H1 2014 excluding Hip activity). International revenue totaled €1,823 thousand and accounted for 55.1% of total 1sthalf revenue (vs. 40.1% in H1 2014), driven by further growth in the United States, which now accounts for 16.5% of total sales compared with 7.2% in H1 2014.
Revenue from Spine activity (JAZZ), the Company’s core business and priority area of development, totaled €1,455 thousand over the half (+65.5%), with JAZZ sales growing across all markets, most notably the United States where revenue jumped +88% to €546 thousand. France, the United States and the rest of the world accounted for 37%, 37% and 26% of Spine revenue over the period. JAZZ sales now account for 44% of sales (vs. 22% in H1 2014).
